Business Context and Reporting Period
Company: Imunon, Inc. (IMNN)
Filing Type: Form 8-K (Current Report)
Date of Report: May 19, 2025
Reporting Period: Event date May 19, 2025
Business Context: The Company received a deficiency notice from The Nasdaq Stock Market LLC regarding non-compliance with listing standards.
Key Financial Metrics
This filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The deficiency notice indicates the Company currently fails to meet the Minimum Stockholders' Equity Requirement of $2,500,000 under Nasdaq Listing Rule 5550(b)(1). The filing also notes the Company does not currently meet alternative compliance standards regarding market value of listed securities or net income from continuing operations.
Material Changes and Listing Status
- Deficiency Notice: On May 19, 2025, Nasdaq notified the Company of non-compliance with the Minimum Stockholders' Equity Requirement.
- Current Trading Status: The notice has no immediate effect; common stock continues to trade on the Nasdaq Capital Market under the symbol "IMNN."
- Compliance Timeline: The Company has 45 calendar days (until July 3, 2025) to submit a plan to regain compliance.
- Extension Possibility: If a plan is accepted, Nasdaq may grant an extension of up to 180 calendar days to evidence compliance.
- Delisting Risk: Failure to submit an acceptable plan or regain compliance within the required timeframe could result in delisting.
- Prior Deficiencies: This notice is unrelated to a previously disclosed deficiency regarding the minimum bid price requirement (reported November 27, 2024).
Outlook, Risks, and Management Commentary
Management Action: The Company is evaluating options to regain compliance and intends to timely submit a plan to Nasdaq.
Risks and Uncertainties:
- There is no assurance the Company will be able to regain compliance with the Minimum Stockholders' Equity Requirement.
- There is no assurance the Company will meet other applicable Nasdaq listing criteria.
- There is no assurance Nasdaq will grant relief from delisting or that the Company can meet requirements for such relief.
Investor Verification Checklist
- Verify the Company's current stockholders' equity balance to confirm the specific shortfall below the $2,500,000 threshold.
- Monitor the submission of the compliance plan by the July 3, 2025 deadline.
- Review the status of the previously disclosed minimum bid price deficiency to assess cumulative listing risks.
- Check for any subsequent filings regarding the acceptance or rejection of the compliance plan by Nasdaq.
- Assess the Company's liquidity and capital raise capabilities to determine the feasibility of meeting equity requirements.